Simply Wall St.
Reassessing United Therapeutics (UTHR) Valuation After Strong 1 Year Share Price Performance
📈
AI Sentiment
Highly Positive
8/10
- Home
- UTHR
as of 01-13-2026 3:38pm EST
$474.88
$7.51
-1.56%
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | SILVER SPRING |
| Market Cap: | 21.4B | IPO Year: | 1999 |
| Target Price: | $498.83 | AVG Volume (30 days): | 471.9K |
| Analyst Decision: | Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 26.38 | EPS Growth: | 16.08 |
| 52 Week Low/High: | $266.98 - $519.99 | Next Earning Date: | 02-25-2026 |
| Revenue: | $3,128,400,000 | Revenue Growth: | 13.50% |
| Revenue Growth (this year): | 13.64% | Revenue Growth (next year): | 5.78% |
AI-Powered UTHR Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 74.51%
74.51%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of United Therapeutics Corporation (UTHR)
BENKOWITZ MICHAEL
Sell
PRESIDENT AND COO
UTHR Jan 12, 2026
Avg Cost/Share
$479.51
Shares
22,500
Total Value
$10,788,876.00
Owned After
0
CAUSEY CHRISTOPHER
Sell
Director
UTHR Jan 6, 2026
Avg Cost/Share
$510.00
Shares
1,000
Total Value
$510,000.00
Owned After
4,190
SEC Form 4
BENKOWITZ MICHAEL
Sell
PRESIDENT AND COO
UTHR Jan 5, 2026
Avg Cost/Share
$487.65
Shares
22,500
Total Value
$10,965,962.12
Owned After
0
MALCOLM JAN
Sell
Director
UTHR Jan 5, 2026
Avg Cost/Share
$495.01
Shares
50
Total Value
$24,750.50
Owned After
370
SEC Form 4
MAHON PAUL A
Sell
EVP & GENERAL COUNSEL
UTHR Jan 2, 2026
Avg Cost/Share
$485.05
Shares
8,300
Total Value
$4,029,076.32
Owned After
43,041
CAUSEY CHRISTOPHER
Sell
Director
UTHR Jan 2, 2026
Avg Cost/Share
$500.01
Shares
1,000
Total Value
$500,014.60
Owned After
4,190
SEC Form 4
BENKOWITZ MICHAEL
Sell
PRESIDENT AND COO
UTHR Dec 29, 2025
Avg Cost/Share
$502.79
Shares
22,500
Total Value
$11,312,709.75
Owned After
0
MAHON PAUL A
Sell
EVP & GENERAL COUNSEL
UTHR Dec 24, 2025
Avg Cost/Share
$512.28
Shares
11,000
Total Value
$5,644,953.77
Owned After
43,041
MALCOLM JAN
Sell
Director
UTHR Dec 23, 2025
Avg Cost/Share
$512.12
Shares
50
Total Value
$25,606.00
Owned After
370
SEC Form 4
SULLIVAN LOUIS W
Sell
Director
UTHR Dec 22, 2025
Avg Cost/Share
$511.78
Shares
5,950
Total Value
$3,047,200.66
Owned After
4,863
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| BENKOWITZ MICHAEL | UTHR | PRESIDENT AND COO | Jan 12, 2026 | Sell | $479.51 | 22,500 | $10,788,876.00 | 0 | |
| CAUSEY CHRISTOPHER | UTHR | Director | Jan 6, 2026 | Sell | $510.00 | 1,000 | $510,000.00 | 4,190 | |
| BENKOWITZ MICHAEL | UTHR | PRESIDENT AND COO | Jan 5, 2026 | Sell | $487.65 | 22,500 | $10,965,962.12 | 0 | |
| MALCOLM JAN | UTHR | Director | Jan 5, 2026 | Sell | $495.01 | 50 | $24,750.50 | 370 | |
| MAHON PAUL A | UTHR | EVP & GENERAL COUNSEL | Jan 2, 2026 | Sell | $485.05 | 8,300 | $4,029,076.32 | 43,041 | |
| CAUSEY CHRISTOPHER | UTHR | Director | Jan 2, 2026 | Sell | $500.01 | 1,000 | $500,014.60 | 4,190 | |
| BENKOWITZ MICHAEL | UTHR | PRESIDENT AND COO | Dec 29, 2025 | Sell | $502.79 | 22,500 | $11,312,709.75 | 0 | |
| MAHON PAUL A | UTHR | EVP & GENERAL COUNSEL | Dec 24, 2025 | Sell | $512.28 | 11,000 | $5,644,953.77 | 43,041 | |
| MALCOLM JAN | UTHR | Director | Dec 23, 2025 | Sell | $512.12 | 50 | $25,606.00 | 370 | |
| SULLIVAN LOUIS W | UTHR | Director | Dec 22, 2025 | Sell | $511.78 | 5,950 | $3,047,200.66 | 4,863 |
Latest United Therapeutics Corporation News
UTHR Breaking Stock News: Dive into UTHR Ticker-Specific Updates for Smart Investing
Zacks
UTHR or MDGL: Which Is the Better Value Stock Right Now?
📈
AI Sentiment
Highly Positive
8/10
Compare UTHR vs Leading Stocks
See how UTHR stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "UTHR United Therapeutics Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.